Abstract: Parenteral (injectable) celecoxib emulsions and nanoemulsions are disclosed as are their use to treat pain in patients so afflicted. The emulsions are generally oil in water emulsions often comprised of an oil phase including an oil and a lecithin wherein the mean droplet size of the discontinuous oil phase is about 200 nanometers or less.

Abstract: The present invention relates to new tricyclic triazolic compounds having a great affinity for sigma receptors, especially sigma-1 receptors, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments.

Abstract: The present invention relates to a pure polymorph of Nor-UDCA or Bis-nor-UDCA, or of a pharmaceutically acceptable salt thereof. The invention further provides a pharmaceutical composition comprising the polymorph of the invention, and a method for preparing the polymorph. The invention includes the pharmaceutical use of the polymorph or of the pharmaceutical composition of the invention.

Abstract: A battery tray (1) has a base for receiving a base (16) of a battery housing (2), opposed side walls (17, 18), an end wall (19) that connects the side walls (17, 18) and a clamp (22) that is connectable to the base (16). The end wall (19) and a first side wall (17) have grooves (24, 23) running parallel to the base (16) for receiving projections (10, 12) of the battery housing (2). The clamp (22) connects to the base (16) on the side of the battery tray (1) that faces away from the end wall (19). The clamp (22) has a block-forming element (29) for positioning the battery housing (2) on the side facing the second side wall (18), and the second side wall (18) has a block-forming element (30) in the region of the end wall (19), for positioning the battery tray (2) on the side facing the second side wall (18).

Abstract: A switchover valve unit (36) for an internal combustion engine that has an adjustable compression ratio for controlling an hydraulic oil stream in hydraulic chambers (22, 23) of an eccentric adjustment device. The hydraulic chambers (22, 23) can be filled with hydraulic oil via hydraulic oil feed lines (24, 25), and ventilation of the hydraulic chambers (23, 24) via hydraulic oil discharge lines (30, 31) is permitted or not permitted depending on a switching position of the switchover valve unit (36). The switchover valve unit (36) having an actuating module (53) with a linearly displaceable pick-off element (37), a valve module (56) with ventilation valves (41, 42) in the hydraulic oil discharge lines (30, 31), and actuating rods (39, 40) that can be displaced linearly by the pick-off element (37). The ventilation valves (41, 42) are opened or closed depending on the switching position of the pick-off element (37).

Abstract: The present invention relates to a synthetic solid bar cleanser formulated to clean human skin. More particularly, the present invention relates to synthetic solid cleanser formulations which have pH of about 5.5, the same as human skin, and yet which perform similarly, or superior, to traditional soap.

Abstract: A lighting device includes a housing, at least one cover panel covering the housing and a plurality of lighting elements disposed in the housing and forming different lighting units. Four of the lighting elements are arranged in a rectangular arrangement with respect to one another so as to form a first lighting unit. The four lighting elements of the first lighting unit including two upper lighting elements disposed adjacent to one another and two lower lighting elements disposed adjacent to one another.

Abstract: The present invention relates, e.g., to a method for inducing arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or for inducing mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte, comprising administering to a cell or tissue in need thereof a dose of a polynucleotide that encodes a vascular endothelial growth factor (VEGF), or that encodes a polypeptide comprising an active site of the VEGF. The coding sequence is operably linked to an expression control sequence; and the dose is sufficient to induce arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or to induce mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte. In preferred embodiments of the invention, the method is a method of tissue regeneration, particularly of cardiomyogenesis; and the polynucleotide (or a polypeptide encoded by such a polynucleotde) is administered into the myocardium.

Abstract: A supporting frame for a motor vehicle has two parallel longitudinal members oriented in the longitudinal direction of the motor vehicle and form part of the body. Two longitudinal struts are oriented at least partially in the longitudinal direction and are fixed at first ends to a contact section of the longitudinal members. The longitudinal struts are connected at a second end opposite the first end to an impact plate that is arranged on at least one driving component of the motor vehicle to form a load path between the contact section of the longitudinal members and the at least one driving component.

Abstract: A drive train for a hybrid motor vehicle has an internal combustion engine (12) with a motor shaft (18) for providing a torque for driving the hybrid motor vehicle, and an electric machine (30) for providing a torque for driving the hybrid motor vehicle. The motor shaft (18) can be coupled via a transmission clutch (14) to a motor vehicle transmission (16) to shift transmission gears (1 to 8), and the motor vehicle transmission (16) has a transmission output shaft (28). A ring gear of a differential gear mechanism (29) of the hybrid motor vehicle can be driven by the transmission output shaft (28). The electric machine (30) can be coupled by a clutch (K3) to a drive shaft (60) and the ring gear (62) can be driven by the drive shaft (60).

Abstract: The invention relates to a resonator for the distribution and partial transformation of longitudinal vibrations and to a method for treating at least one fluid by means of a resonator according to the invention. The resonator is designed for the distribution of longitudinal vibrations and the partial transformation thereof into longitudinal vibrations that are superimposed by vibrations oriented towards the center of gravity or approximately towards the center of gravity of a cross-sectional surface of at least one opening of the resonator. The resonator comprises a natural number of parallel elements of at least lambda/2 or a natural multiple thereof, at least one of the lambda/2 elements comprising at least one opening suitable for transmitting the transformed vibrations to a fluid located inside the opening.

Abstract: The present invention relates to new indene derivatives of formula (I) having a great affinity for sigma receptors, especially sigma-1 receptors, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments.

Abstract: Disclosed is an optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus. A pharmaceutical formulation in the form of an orodispersible effervescent tablet is stable, easy to produce, and can be used without dissolving same in a liquid. It is not necessary to drink anything with the tablet as this would reduce the time that the budesonide solution remains in the affected regions of the esophagus. The effervescent tablet of the invention surprisingly resulted in an unexpectedly high rate of histological remission in patients with active eosinophilic esophagitis.

Abstract: The present invention relates to a series of substituted compounds having the general formula (I), including their stereoisomers and/or their pharmaceutically acceptable salts, wherein R1, R2, R3, R4, R5, and R6 are as defined herein. This invention also relates to methods of making these compounds including intermediates. The compounds of this invention are effective at the kappa (?) opioid receptor (KOR) site. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic pain, and associated disorders, particularly functioning peripherally at the CNS.

Abstract: The present invention relates to new substituted pyrazolo[1,5-a]pyridine having a great affinity for sigma receptors, especially sigma-1 receptor, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments.